AKBA Akebia Therapeutics, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

AKBA [NASD]

Akebia Therapeutics, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-3.01	Insider Own	0.30%	Shs Outstand	136.91M	Perf Week	-4.87%
Market Cap	378.00M	Forward P/E	-	EPS next Y	-0.67	Insider Trans	-4.31%	Shs Float	134.72M	Perf Month	-73.76%
Income	-385.60M	PEG	-	EPS next Q	-0.17	Inst Own	80.20%	Short Float	6.06%	Perf Quarter	-79.37%
Sales	340.20M	P/S	1.11	EPS this Y	4.50%	Inst Trans	18.78%	Short Ratio	1.77	Perf Half Y	-66.80%
Book/sh	2.70	P/B	0.94	EPS next Y	71.20%	ROA	-49.80%	Target Price	-	Perf Year	-41.74%
Cash/sh	1.98	P/C	1.28	EPS next 5Y	-	ROE	-94.70%	52W Range	2.46 - 13.71	Perf YTD	-59.81%
Dividend	-	P/FCF	-	EPS past 5Y	21.70%	ROI	-59.40%	52W High	-81.73%	Beta	1.64
Dividend %	-	Quick Ratio	1.80	Sales past 5Y	-	Gross Margin	61.70%	52W Low	1.83%	ATR	0.55
Employees	360	Current Ratio	2.30	Sales Q/Q	-10.60%	Oper. Margin	-	RSI (14)	17.93	Volatility	10.48% 7.78%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-161.00%	Profit Margin	-	Rel Volume	1.30	Prev Close	2.54
Shortable	Yes	LT Debt/Eq	0.21	Earnings	Aug 10 BMO	Payout	-	Avg Volume	4.60M	Price	2.51
Recom	2.20	SMA20	-49.20%	SMA50	-71.27%	SMA200	-71.95%	Volume	4,390,576	Change	-1.38%

Nov-14-19

Reiterated

Needham

Buy

$18 → $15

Aug-06-19

Reiterated

H.C. Wainwright

Buy

$19 → $17

Jul-11-19

Reiterated

H.C. Wainwright

Buy

$23 → $21

May-02-19

Initiated

JP Morgan

Overweight

$12

Mar-20-19

Initiated

Citigroup

Neutral

Sep-07-18

Resumed

Morgan Stanley

Equal-Weight

Aug-10-18

Reiterated

Needham

Buy

$20 → $18

Jun-06-18

Reiterated

H.C. Wainwright

Buy

$24 → $22

Dec-19-17

Initiated

Piper Jaffray

Overweight

$26

Dec-07-17

Initiated

BTIG Research

Buy

$30

Sep-15-17

Initiated

RBC Capital Mkts

Sector Perform

$17

Jul-10-17

Reiterated

H.C. Wainwright

Buy

$25 → $24

Apr-27-17

Reiterated

Needham

Buy

$14 → $18

Apr-27-17

Reiterated

H.C. Wainwright

Buy

$18 → $21

Dec-27-16

Reiterated

H.C. Wainwright

Buy

$17 → $18

Dec-20-16

Reiterated

JMP Securities

Mkt Outperform

$16 → $19

Nov-15-16

Initiated

Aegis Capital

Buy

Sep-29-16

Initiated

Brean Capital

Buy

Mar-16-16

Reiterated

Needham

Buy

$18 → $14

Jan-21-16

Initiated

Credit Suisse

Neutral

Sep-08-20 08:00AM	Akebia Therapeutics Announces September 2020 Investor Conference Schedule PR Newswire
Sep-04-20 12:55PM	Akebia Falls as Vadadustat Fails to Meet Safety Endpoint Zacks
Sep-03-20 11:55AM	Why Akebia Therapeutics Stock Is Crashing Today Motley Fool -73.50%
09:53AM	ROCE Insights For Akebia Therapeutics Benzinga
07:00AM	Akebia Therapeutics Announces Top-Line Results from its PRO2TECT Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients Not on Dialysis PR Newswire
Sep-02-20 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Aug-26-20 08:41AM	Implied Volatility Surging for Akebia (AKBA) Stock Options Zacks
08:00AM	Akebia Therapeutics Announces First Commercial Launch of VAFSEO (vadadustat tablets), a New Oral Treatment for Anemia Due to Chronic Kidney Disease, in Japan PR Newswire
Aug-12-20 07:08AM	If You Had Bought Akebia Therapeutics (NASDAQ:AKBA) Stock A Year Ago, You Could Pocket A 132% Gain Today Simply Wall St.
07:07AM	Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Path To Profitability Simply Wall St.
Aug-10-20 05:55PM	Akebia Therapeutics (AKBA) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:01PM	Akebia Reports Second Quarter 2020 Financial Results PR Newswire
Aug-07-20 09:30AM	Were Hedge Funds Right About Warming Up To Akebia Therapeutics Inc (AKBA)? Insider Monkey
Aug-03-20 08:00AM	Akebia Therapeutics to Report Second Quarter 2020 Financial Results PR Newswire
Jul-14-20 10:32AM	Akebia Initiates Vadadustat Study In Covid-19 Patients SmarterAnalyst
08:00AM	Akebia Announces Initiation of Investigator-Sponsored Study Evaluating Vadadustat for Prevention and Treatment of ARDS in Patients Hospitalized with COVID-19 PR Newswire
Jul-06-20 09:37AM	What Is The Ownership Structure Like For Akebia Therapeutics, Inc. (NASDAQ:AKBA)? Simply Wall St.
Jul-02-20 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Jun-29-20 07:40AM	Akebia Therapeutics Announces Approval of Vadadustat in Japan for the Treatment of Anemia Due to Chronic Kidney Disease in Dialysis-Dependent and Non-Dialysis Dependent Adult Patients PR Newswire +8.73%
Jun-23-20 01:22PM	Hedge Funds Are Buying Akebia Therapeutics Inc (AKBA) Insider Monkey
Jun-22-20 08:00AM	Akebia Therapeutics Launches AkebiaShares, a Peer-to-Peer Educational Program Series for the Renal Community PR Newswire +6.09%
Jun-18-20 04:01PM	Akebia Therapeutics Announces New Chief Financial Officer PR Newswire
Jun-16-20 11:30AM	Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year? Zacks
Jun-12-20 12:00PM	Akebia Therapeutics (AKBA) Upgraded to Buy: Here's What You Should Know Zacks +6.27%
Jun-10-20 08:00AM	Akebia Therapeutics Announces Data on Different Dosing Regimens of Ferric Citrate for Iron Deficiency Anemia Presented at 57th ERA-EDTA Virtual Congress PR Newswire
Jun-02-20 04:30PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
07:14AM	Edited Transcript of AKBA earnings conference call or presentation 10-Mar-20 1:00pm GMT Thomson Reuters StreetEvents
May-27-20 02:38AM	Edited Transcript of AKBA earnings conference call or presentation 5-May-20 12:30pm GMT Thomson Reuters StreetEvents
May-26-20 08:00AM	Akebia Therapeutics to Present at Jefferies Virtual Global Healthcare Conference PR Newswire
May-21-20 04:05PM	Akebia Therapeutics Announces Change to Virtual Annual Meeting of Stockholders PR Newswire
May-19-20 04:05PM	Akebia Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire
May-18-20 08:00AM	Akebia Therapeutics Announces Collaboration Partner's Submission of Supplemental New Drug Application for Use of Riona® (ferric citrate hydrate) to Treat Adult Patients with Iron Deficiency Anemia in Japan PR Newswire
May-13-20 11:37AM	Akebia Therapeutics, Inc. (AKBA) Shares March Higher, Can It Continue? Zacks
May-11-20 09:15PM	Akebia Therapeutics Announces Pricing of Upsized Public Offering of Common Stock PR Newswire +7.26%
04:01PM	Akebia Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
08:36AM	How Akebia Therapeutics (AKBA) Stock Stands Out in a Strong Industry Zacks
May-08-20 08:00AM	Akebia Therapeutics to Present at RBC Capital Markets Global Healthcare Virtual Conference PR Newswire
May-07-20 02:15PM	US$17.13 - That's What Analysts Think Akebia Therapeutics, Inc. (NASDAQ:AKBA) Is Worth After These Results Simply Wall St.
11:24AM	Akebia Shares Climb on Positive Anemia Drug Study Results GuruFocus.com
May-06-20 01:49AM	Akebia Spikes 38% On Pivotal Trial Readout; And Further Upside Lies Ahead SmarterAnalyst
May-05-20 06:00PM	Akebia Therapeutics Inc (AKBA) Q1 2020 Earnings Call Transcript Motley Fool +37.99%
11:50AM	Why Akebia Therapeutics Stock Is Crushing It Today Motley Fool
09:45AM	Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates Zacks
09:38AM	Recap: Akebia Therapeutics Q1 Earnings Benzinga
07:30AM	Akebia Announced Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis; Reports First Quarter 2020 Financial Results PR Newswire
07:21AM	Akebia's shares jump on late-stage clinical trial results for kidney disease drug MarketWatch
May-04-20 04:30PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire +8.52%
Apr-28-20 08:00AM	Akebia Therapeutics to Report First Quarter 2020 Financial Results and Discuss Recent Business Highlights PR Newswire
Apr-17-20 06:44AM	Does Akebia Therapeutics (NASDAQ:AKBA) Have A Healthy Balance Sheet? Simply Wall St. +5.82%
Apr-14-20 04:41PM	Seth Klarman Dials Down Akebia Therapeutics Stake GuruFocus.com +8.12%
Apr-10-20 06:31PM	INVESTOR ALERT: Fields Kupka & Shukurov LLP Is Investigating Akebia Therapeutics, Inc. for Potential Breach of Fiduciary Duty Claims. GlobeNewswire
Apr-07-20 08:00AM	Akebia Therapeutics Appoints Myles Wolf, M.D., M.M.Sc., Chief of Nephrology and Professor at Duke University School of Medicine, to Board of Directors PR Newswire -5.50%
Apr-02-20 04:30PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire +6.00%
10:00AM	Is the Options Market Predicting a Spike in Akebia Therapeutics (AKBA) Stock? Zacks
Mar-23-20 08:00AM	Akebia Therapeutics to Present Research at NKF 2020 Spring Clinical Meetings Live Virtual Conference PR Newswire +6.68%
Mar-15-20 09:28PM	A Message from Akebia Therapeutics, Inc.s Chief Executive Officer to Our Patients, Healthcare Providers, and Other Stakeholders During the Rapidly Evolving COVID-19 Pandemic: Business Wire
Mar-12-20 06:20AM	Akebia Therapeutics, Inc. Just Released Its Yearly Results And Analysts Are Updating Their Estimates Simply Wall St. -12.54%
Mar-10-20 09:15AM	Akebia Therapeutics (AKBA) Reports Q4 Loss, Misses Revenue Estimates Zacks -7.70%
07:49AM	Akebia Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Hosts Conference Call to Discuss Recent Business Highlights Business Wire
07:00AM	Akebia Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-03-20 12:30PM	Will Akebia Therapeutics (AKBA) Report Negative Earnings Next Week? What You Should Know Zacks
Mar-02-20 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Mar-01-20 07:04AM	One Thing To Remember About The Akebia Therapeutics, Inc. (NASDAQ:AKBA) Share Price Simply Wall St.
Feb-25-20 09:41AM	Is the Options Market Predicting a Spike in Akebia Therapeutics (AKBA) Stock? Zacks -10.91%
Feb-24-20 08:00AM	Akebia Therapeutics to Report Fourth Quarter and Full-Year 2019 Financial Results and Discuss Recent Business Highlights Business Wire
Feb-04-20 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jan-31-20 07:10AM	Akebia Therapeutics, Inc. (NASDAQ:AKBA) Insiders Increased Their Holdings Simply Wall St.
Jan-06-20 08:00AM	Akebia Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference Business Wire
Jan-03-20 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jan-01-20 05:14AM	Analysts Expect Breakeven For Akebia Therapeutics, Inc. (NASDAQ:AKBA) Simply Wall St.
Dec-11-19 01:57PM	Did Hedge Funds Drop The Ball On Akebia Therapeutics Inc (AKBA) ? Insider Monkey
Dec-10-19 12:22PM	Seth Klarman Pares Paratek Pharmaceuticals Stake GuruFocus.com +7.91%
Dec-03-19 04:06PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire +14.10%
Dec-02-19 08:57AM	Options Traders Expect Huge Moves in Akebia Therapeutics (AKBA) Stock Zacks -15.42%
05:09AM	Introducing Akebia Therapeutics (NASDAQ:AKBA), The Stock That Slid 52% In The Last Five Years Simply Wall St.
Nov-27-19 09:45AM	5 Strong Buy Biotech Stocks With More Than 80% Upside InvestorPlace +11.67%
Nov-26-19 12:26PM	Large Option Trader Betting On Biotech Stock Akebia Following Insider Buys Benzinga
Nov-21-19 08:00AM	Akebia Therapeutics to Present at Upcoming Investor Conferences Business Wire
Nov-20-19 05:28PM	Edited Transcript of AKBA earnings conference call or presentation 12-Nov-19 2:00pm GMT Thomson Reuters StreetEvents +5.03%
Nov-12-19 09:15AM	Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates Zacks -9.02%
07:57AM	Akebia Secures $100 Million Non-Dilutive Term Loan Financing; Reports Third Quarter 2019 Financial Results Business Wire
07:20AM	The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat Benzinga
Nov-09-19 12:15PM	Akebia Announces Positive 52-week Efficacy and Safety Data for Vadadustat from Two Pivotal Phase 3 Studies in Japanese Patients with Anemia Due to Chronic Kidney Disease Business Wire
Nov-05-19 10:33AM	Will Akebia Therapeutics (AKBA) Report Negative Earnings Next Week? What You Should Know Zacks
Nov-04-19 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Nov-01-19 09:18AM	Can Akebia Therapeutics (NASDAQ:AKBA) Afford To Invest In Growth? Simply Wall St.
Oct-30-19 09:30AM	Akebia Therapeutics Inc (AKBA) Is Burning These Hedge Funds Insider Monkey
Oct-28-19 08:00AM	Akebia Therapeutics to Report Third Quarter 2019 Financial Results and Discuss Recent Business Highlights Business Wire
Oct-24-19 08:00AM	Akebia Announces Nine Abstracts Accepted for Presentation at the American Society of Nephrology Kidney Week 2019 Annual Meeting Business Wire -6.52%
Oct-16-19 07:06AM	The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch Benzinga
Oct-15-19 04:46PM	Akebia Files Lawsuit Against CMS for 2018 Action Rescinding Medicare Part D Coverage of FDA-Approved Auryxia® for its Iron Deficiency Anemia Indication and Imposing a Prior Authorization Requirement for its Hyperphosphatemia Indication Business Wire
Oct-02-19 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
12:27PM	Should You Worry About Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) CEO Pay Cheque? Simply Wall St.
Sep-24-19 08:00AM	Akebia Therapeutics to Present at the 2019 Cantor Global Healthcare Conference Business Wire
Sep-11-19 10:16PM	Edited Transcript of AKBA earnings conference call or presentation 8-Aug-19 1:00pm GMT Thomson Reuters StreetEvents
Sep-04-19 05:15PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Sep-03-19 02:21PM	In expense-laden biotech industry, here are the Mass. startups most in need of cash American City Business Journals
Sep-02-19 03:41PM	How Does Akebia Therapeutics, Inc. (NASDAQ:AKBA) Affect Your Portfolio Volatility? Simply Wall St.
Aug-09-19 11:51PM	Akebia Therapeutics, Inc. (AKBA) Q2 2019 Earnings Call Transcript Motley Fool +5.76%
08:00AM	Akebia Therapeutics to Participate in Upcoming Investor Conferences Business Wire

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. It has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds worldwide. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GOWEN MAXINE	Director	Jun 08	Sale	12.05	4,567	55,032	24,133	Jun 09 04:17 PM
GILMAN STEVEN C	Director	Jun 08	Sale	12.08	4,567	55,169	38,864	Jun 09 04:17 PM
Smith Cynthia	Director	Jun 08	Sale	12.10	4,567	55,261	37,833	Jun 09 04:17 PM
Faulkingham Dell	CCO	Jun 01	Sale	11.58	6,426	74,413	73,574	Jun 02 04:34 PM
Hadas Nicole R.	SVP, Chief Legal Officer	Feb 28	Sale	8.70	7,050	61,335	212,756	Mar 02 07:28 PM
Dahan Michel	SVP, Chief Operating Officer	Feb 28	Sale	8.70	6,972	60,656	204,960	Mar 02 07:29 PM
Amello Jason	SVP, CFO & Treasurer	Feb 28	Sale	8.70	6,976	60,691	144,642	Mar 02 07:27 PM
Tubridy Karen L	SVP, Chief Development Officer	Feb 28	Sale	8.70	3,454	30,050	84,679	Mar 02 07:26 PM
Burke Steven Keith	SVP, Chief Medical Officer	Nov 20	Buy	3.58	27,000	96,660	37,000	Nov 22 06:19 AM
Smith Cynthia	Director	Nov 20	Buy	3.52	15,000	52,800	28,700	Nov 22 06:20 AM
GILMAN STEVEN C	Director	Nov 20	Buy	3.43	5,800	19,894	29,731	Nov 22 06:20 AM
Butler John P.	CEO and President	Nov 20	Buy	3.44	50,000	172,000	887,732	Nov 21 06:32 AM
ADAMS ADRIAN	Director	Nov 20	Buy	3.41	50,000	170,500	63,700	Nov 21 06:31 AM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience